Jazz Pharmaceuticals JAZZ Maximum allowable dividend and restricted payments
Maximum allowable dividend and restricted payments at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:DebtInstrumentCovenantMaximumAllowableDividendAndRestrictedPayments.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's maximum allowable dividend and restricted payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's maximum allowable dividend and restricted payments?
- Jazz Pharmaceuticals (JAZZ) reported maximum allowable dividend and restricted payments of $87.5M in Q4 2025.
- How has Jazz Pharmaceuticals's maximum allowable dividend and restricted payments changed year-over-year?
- Jazz Pharmaceuticals's maximum allowable dividend and restricted payments decreased by 0.0% year-over-year, from $87.5M to $87.5M.
- What is the long-term trend for Jazz Pharmaceuticals's maximum allowable dividend and restricted payments?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's maximum allowable dividend and restricted payments has grown at a 84.8% compound annual growth rate (CAGR), from $30M to $350M.
- What does maximum allowable dividend and restricted payments mean?
- The maximum dollar amount a company is permitted to pay out in dividends or share repurchases under its debt contracts.
- How do you interpret maximum allowable dividend and restricted payments?
- A higher limit provides greater flexibility for capital returns, while a lower limit indicates stricter creditor constraints on cash outflows.
- How does maximum allowable dividend and restricted payments compare across companies?
- Common in companies with significant leverage; peers often have similar restrictive covenants based on retained earnings or cash flow thresholds.